GH1 and metabolic dysfunction-associated steatohepatitis: By expanding our knowledge of the effects of GH axis augmentation on hepatic biology, our findings raise the possibility of novel clinical benefits of this strategy in the treatment of NASH that should be evaluated in future large-scale efforts.